4.7 Article

Untangling the association of amyloid-beta and tau with synaptic and axonal loss in Alzheimer's disease

期刊

BRAIN
卷 144, 期 -, 页码 310-324

出版社

OXFORD UNIV PRESS
DOI: 10.1093/brain/awaa395

关键词

neurogranin; neurofilament; amyloid-beta; PET; tau PET; MRI

资金

  1. Swedish Research Council
  2. Knut and Alice Wallenberg foundation
  3. Marianne and Marcus Wallenberg foundation
  4. Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
  5. Swedish Alzheimer Foundation
  6. Swedish Brain Foundation
  7. Demensfonden
  8. Eivind och Elsa K: son Sylvans stiftelse
  9. Martha och Gustaf Agrens stiftelse
  10. Gun och Bertil Stohnes stiftelse
  11. Stiftelsen Gamla Tjanarinnor
  12. Parkinson foundation of Sweden
  13. Parkinson Research Foundation
  14. Skane University Hospital Foundation
  15. Swedish federal government under the ALF agreement
  16. GE Healthcare
  17. Swedish Research Council [2018-02201, 2017-00915, 2018-02532]
  18. Hjarnfonden [FO2019-0289]
  19. Alzheimerfonden [AF-930827]
  20. Strategic Research Programme in Neuroscience at Karolinska Institutet (Stratneuro Startup Grant)
  21. Center for Medical Innovation [20200695]
  22. Gamla Tjanarinnor [201900803]
  23. Stohnes
  24. Alzheimer Drug Discovery Foundation (ADDF), USA [RDAPB-2018092016615]
  25. Swedish Alzheimer Foundation [AF742881]
  26. Hjarnfonden, Sweden [FO2017-0243]
  27. Swedish government [ALFGBG-715986]
  28. Swedish County Councils, the ALF [ALFGBG-715986]
  29. European Union Joint Program for Neurodegenerative Disorders [JPND2019-466-236]
  30. European Research Council [681712]
  31. Swedish State Support for Clinical Research [ALFGBG-720931]
  32. UK Dementia Research Institute at UCL

向作者/读者索取更多资源

The study found that in early Alzheimer's disease, presynaptic and postsynaptic markers are elevated and associated with more severe amyloid-beta pathology, memory decline, and changes in the default mode network. In later disease stages, abnormal levels of neurofilament light chain were observed, correlated with more tau pathology and worse global cognition.
It is currently unclear how amyloid-beta and tau deposition are linked to changes in synaptic function and axonal structure over the course of Alzheimer's disease. Here, we assessed these relationships by measuring presynaptic (synaptosomal-associated protein 25, SNAP25; growth-associated protein 43, GAP43), postsynaptic (neurogranin, NRGN) and axonal (neurofilament light chain) markers in the CSF of individuals with varying levels of amyloid-beta and tau pathology based on F-18-flutemetamol PET and F-18-flortaucipir PET. In addition, we explored the relationships between synaptic and axonal markers with cognition as well as functional and anatomical brain connectivity markers derived from resting-state functional MRI and diffusion tensor imaging. We found that the presynaptic and postsynaptic markers SNAP25, GAP43 and NRGN are elevated in early Alzheimer's disease i.e. in amyloid-beta-positive individuals without evidence of tau pathology. These markers were associated with greater amyloid-beta pathology, worse memory and functional changes in the default mode network. In contrast, neurofilament light chain was abnormal in later disease stages, i.e. in individuals with both amyloid-beta and tau pathology, and correlated with more tau and worse global cognition. Altogether, these findings support the hypothesis that amyloid-beta and tau might have differential downstream effects on synaptic and axonal function in a stage-dependent manner, with amyloid-related synaptic changes occurring first, followed by tau-related axonal degeneration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据